Reference
- Buda A, et al. Infliximab dose-reduction in inflammatory bowel disease (IBD) patients in prolonged deep remission: Potential implications on de-escalation strategies in a real-life clinical setting without a therapeutic drug monitoring (TDM) approach. United European Gastroenterology Journal 6 (Suppl.): A655-A656 (plus poster) abstr. P1603, No. 8, Oct 2018. Available from: URL: http://doi.org/10.1177/2050640618792819 [abstract] - Italy
Copyright information
© Springer Nature Switzerland AG 2019